MXPA02004505A - Peptidos mimeticos para epitope de apolipoproteinab-100 concatamero y peptidos modificados del mismo, y la composicion de vacuna que comprende los mismos. - Google Patents

Peptidos mimeticos para epitope de apolipoproteinab-100 concatamero y peptidos modificados del mismo, y la composicion de vacuna que comprende los mismos.

Info

Publication number
MXPA02004505A
MXPA02004505A MXPA02004505A MXPA02004505A MXPA02004505A MX PA02004505 A MXPA02004505 A MX PA02004505A MX PA02004505 A MXPA02004505 A MX PA02004505A MX PA02004505 A MXPA02004505 A MX PA02004505A MX PA02004505 A MXPA02004505 A MX PA02004505A
Authority
MX
Mexico
Prior art keywords
peptides
concatemer
apolipoprotein
epitope
same
Prior art date
Application number
MXPA02004505A
Other languages
English (en)
Inventor
Kim Hyo-Joon
Original Assignee
Kim Hyo-Joon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kim Hyo-Joon filed Critical Kim Hyo-Joon
Priority claimed from KR10-2001-0054005A external-priority patent/KR100472841B1/ko
Publication of MXPA02004505A publication Critical patent/MXPA02004505A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a composiciones de vacuna para tratar la obesidad; mas particularmente, la presente invencion se dirige a metodos para epitopes de apolipoproteina B-100, concatamero y peptidos modificados de los mismos, y la composicion de vacuna que comprende a los mismos.
MXPA02004505A 2000-09-04 2001-09-04 Peptidos mimeticos para epitope de apolipoproteinab-100 concatamero y peptidos modificados del mismo, y la composicion de vacuna que comprende los mismos. MXPA02004505A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20000052055 2000-09-04
PCT/KR2001/001492 WO2002020040A1 (en) 2000-09-04 2001-09-04 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
KR10-2001-0054005A KR100472841B1 (ko) 2000-09-04 2001-09-04 아포지단백질 비-100의 에피토프에 대한 모조 펩타이드,그들의 연쇄물 또는 변형체와 이들을 함유하는 백신 조성물

Publications (1)

Publication Number Publication Date
MXPA02004505A true MXPA02004505A (es) 2004-09-10

Family

ID=26638363

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02004505A MXPA02004505A (es) 2000-09-04 2001-09-04 Peptidos mimeticos para epitope de apolipoproteinab-100 concatamero y peptidos modificados del mismo, y la composicion de vacuna que comprende los mismos.

Country Status (18)

Country Link
US (1) US6825318B2 (es)
EP (1) EP1315517B1 (es)
JP (1) JP2004508029A (es)
CN (1) CN1231262C (es)
AU (1) AU8628601A (es)
BG (1) BG106655A (es)
BR (1) BR0107175A (es)
CA (1) CA2389739A1 (es)
CZ (1) CZ20021571A3 (es)
EE (1) EE200200238A (es)
HU (1) HUP0203251A2 (es)
IL (1) IL149379A0 (es)
LT (1) LT4989B (es)
MX (1) MXPA02004505A (es)
NO (1) NO20022147L (es)
RU (1) RU2313536C2 (es)
SK (1) SK6312002A3 (es)
WO (1) WO2002020040A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636356A1 (en) * 2003-06-11 2006-03-22 Schering Aktiengesellschaft Novel modified corin molecules having substitute activation sequences and uses thereof
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
US20070054298A1 (en) * 2005-08-12 2007-03-08 Kent Kirshenbaum Methods for enzyme-mediated coupling of oligomers
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
WO2007075335A2 (en) * 2005-12-16 2007-07-05 The Regents Of The University Of California Modulation of in utero immune programming
US20110002955A1 (en) * 2006-09-25 2011-01-06 Sj Biomed Inc. Anti-obese immunogenic hybrid polypeptides and anti-obese vaccine composition comprising the same
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
EP3463416A1 (en) 2016-05-31 2019-04-10 CardioVax, LLC Methods for diagnosing and treating systemic lupus erythematosus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975792B1 (en) * 1997-03-04 2007-10-10 Savient Pharmaceuticals, Inc. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
AU2801299A (en) * 1998-03-04 1999-09-20 Bio-Technology General Corporation Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
HUP0300099A3 (en) * 2000-03-03 2004-10-28 Smithkline Beecham Biolog Vaccine for the treatment of artherosclerosis

Also Published As

Publication number Publication date
SK6312002A3 (en) 2002-09-10
JP2004508029A (ja) 2004-03-18
HUP0203251A2 (hu) 2003-01-28
AU8628601A (en) 2002-03-22
EP1315517A4 (en) 2005-02-09
CN1392798A (zh) 2003-01-22
US6825318B2 (en) 2004-11-30
IL149379A0 (en) 2002-11-10
NO20022147D0 (no) 2002-05-03
CA2389739A1 (en) 2002-03-14
NO20022147L (no) 2002-05-03
CZ20021571A3 (cs) 2002-09-11
EP1315517B1 (en) 2010-10-20
BG106655A (bg) 2004-08-31
BR0107175A (pt) 2002-07-02
RU2003109439A (ru) 2004-07-20
RU2313536C2 (ru) 2007-12-27
CN1231262C (zh) 2005-12-14
WO2002020040A1 (en) 2002-03-14
EP1315517A1 (en) 2003-06-04
US20030211997A1 (en) 2003-11-13
EE200200238A (et) 2003-06-16
LT2002051A (en) 2002-09-25
LT4989B (lt) 2003-01-27

Similar Documents

Publication Publication Date Title
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
MXPA02006029A (es) Lipopeptidos novedosos como agentes antibacterianos.
TWI262925B (en) GLP-1 analogues
MY136707A (en) Thrombopoietin mimetics
SG125915A1 (en) Analogues of glp-1
HU9601449D0 (en) Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
WO2003072593A3 (en) Bone targeting peptides
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
MXPA02004505A (es) Peptidos mimeticos para epitope de apolipoproteinab-100 concatamero y peptidos modificados del mismo, y la composicion de vacuna que comprende los mismos.
EP1423414A4 (en) NEW DEPSIPEPTIDES AND METHOD FOR THE PRODUCTION THEREOF
AP2049A (en) Medicament containing activated antithrombin III
IL156799A0 (en) Peptides having affinity for the gp120 viral protein and use thereof
AU2003283160A8 (en) Shrew paralytic peptide for use in neuromuscular therapy
DE60215917D1 (de) Tripepide und tripepdid-derivte zur behandlung von neurodegenerativen erkrankungen
ES2176334T3 (es) El uso de gabapentin en el tratamiento de la ansiedad y el panico.
DE60205629D1 (en) Akarizidpulver
PT1326838E (pt) Novas formas cristalinas de um inibidor do factor xa
TR200103240T2 (tr) Endoparazit öldürücü bileşimler.
DE69712907D1 (de) Immunogene tlp-zusammensetzung
AU2000265052A1 (en) Somatostatin analogs for the treatment of cancer
ATE285244T1 (de) Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems
AU6871501A (en) Cgi-69 compositions and methods of use
MXPA03010821A (es) Composiciones de aroma y fragancias.
EP1117681A4 (en) NEW PEPTIDES